Inhibition of PARP1 and NAMPT activity by Olaparib and FK-866, respectively, reversed Th2 cytokine-induced epidermal and inflammatory skin damage in our human organotypic 3D skin model of AD. This evidence concerns the gene PARP1 and Alzheimer disease.